# Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

> **NCT01463059** · PHASE2 · COMPLETED · sponsor: **UCB Japan Co. Ltd.** · enrollment: 119 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Olokizumab 60 mg
- **BIOLOGICAL:** Olokizumab 120 mg
- **BIOLOGICAL:** Olokizumab 240 mg

## Key facts

- **NCT ID:** NCT01463059
- **Lead sponsor:** UCB Japan Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2013-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01463059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01463059, "Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01463059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*